Találati lista | Tudóstér

001-es BibID:	BIBFORM028489
Első szerző:	Lakatos Péter (Semmelweis Egyetem)
Cím:	DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease / Lakatos P. L., Fischer S., Claes K., Kovacs A., Molnar T., Altorjay I., Demeter P., Tulassay Z., Palatka K., Papp M., Rutgeerts P., Szalay F., Papp J., Vermeire S., Lakatos L., The Hungarian IBD Study Group
Dátum:	2006
ISSN:	1078-0998
Megjegyzések:	Recent data suggest that haplotypic variants of the DLG5 gene on 10q23 are associated with susceptibility to inflammatory bowel disease (IBD) in Germany. In view of the geographical differences in frequency of genetic markers and the absence of data in Central European patients, our aim was to determine the DLG5 R30Q variant in Hungarian IBD patients. MATERIALS AND METHODS: We investigated 773 unrelated IBD patients (age 38.1 +/- 10.3 years; duration, 8.8 +/- 7.5 years; Crohn's disease [CD]: 639; male/female, 309/330; duration, 8.4 +/- 7.1 years; ulcerative colitis [UC]: 134; male/female, 63/71; duration, 10.6 +/- 8.9 years) and 150 healthy subjects. DLG5 R30Q and TLR4 D299G variants were tested by polymerase chain reaction/restriction fragment length polymorphism. DNA was screened for NOD2/CARD15 mutations by denaturing high-performance liquid chromatography. Detailed clinical phenotype was determined by reviewing the medical charts. RESULTS: The frequency of the R30Q variant allele was not significantly different in IBD (22.0%), CD (20.8%), and UC (27.6%) patients compared with healthy control subjects (28.0%). In CD, the 113A variant allele was associated with steroid resistance (16.3% vs noncarriers, 7.6%; odds ratio [OR], 2.4; 95% CI 1.3-4.5; P = 0.013). In a logistic regression model carriage of DLG5 R30Q, perianal involvement and frequent relapses were independently associated with steroid resistance. No phenotype-genotype associations were found in UC patients, although a trend toward more extensive disease was observed in carriers of the variant allele (OR = 2.1; 95% CI 0.95-4.4; P = 0.07). CONCLUSIONS: The present data strongly contrast previous data from Germany. DLG5 113A is not associated with disease susceptibility, but there was a tendency for this allele to confer resistance to steroids. Further studies are required to evaluate the significance of DLG5 in other populations from geographically diverse regions.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Inflammatory Bowel Diseases. - 12 : 5 (2006), p. 362-368. -
További szerzők:	Fischer Simon Claes, Karolien Kovács Ágota Molnár Tamás (orvos Szeged) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Demeter Pál Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Rutgeerts, Paul Szalay Ferenc (belgyógyász) Papp János (Budapest) Vermeire, S. Lakatos László (Veszprém) The Hungarian IBD Study Group
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM019953
Első szerző:	Lakatos Péter (Semmelweis Egyetem)
Cím:	Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease / Lakatos P. L., Kiss L. S., Palatka K., Altorjay I., Antal-Szalmas P., Palyu E., Udvardy M., Molnar T., Farkas K., Veres G., Harsfalvi J., Papp J., Papp M.
Dátum:	2011
Megjegyzések:	In inflammatory bowel disease (IBD), enhanced inflammatory activity in the gut is thought to increase the risk of bacterial translocation and endotoxemia. In the present study we investigated the association between serum level of lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14), and clinical disease activity, high-sensitivity C-reactive protein (hs-CRP), antimicrobial serology profile, NOD2/CARD15 status, and clinical phenotype in a large cohort of Hungarian Crohn's disease (CD) patients. METHODS: In all, 214 well-characterized, unrelated, consecutive CD patients (male/female ratio: 95/119; age: 35.6 ± 13.1 years; duration:8.3 ± 7.5 years) and 110 healthy controls were investigated. Sera were assayed for LBP, sCD14, hs-CRP, ASCA IgG/IgA, anti-OMP IgA, and pANCA antibodies. NOD2/CARD15 and TLR4 variants were tested. Detailed clinical phenotypes were determined by reviewing the patients' medical charts. RESULTS: Serum LBP level was significantly higher (P < 0.0001 for both), while sCD14 was lower (P < 0.0001) in both active and inactive CD compared to the controls. The accuracy of hs-CRP (area under the curve [AUC] = 0.66), sCD14 (AUC = 0.70), and LBP (AUC = 0.58) was comparable for identifying patients with active disease. There was a significant correlation between LBP (P < 0.001), sCD14 (P = 0.015), and hs-CRP levels but not with antimicrobial seroreactivity or NOD2/CARD15 genotype. In inactive CD, LBP was associated with penetrating disease. In a Kaplan-Meier analysis and a proportional Cox-regression analysis, LBP (P = 0.006), sCD14 (P = 0.007), and previous relapse frequency (P = 0.023) were independently associated with time to clinical relapse during a 12-month follow-up period. CONCLUSIONS: Serum LBP and sCD14 are markers of disease activity in CD with a similar accuracy as hs-CRP. In addition, LBP, sCD14, and a high frequency of previous relapses were independent predictors for 1-year clinical flare-up. (Inflamm Bowel Dis 2011).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Inflammatory Bowel Disease. - 17 : 3 (2011), p. 767-777. -
További szerzők:	Kiss Lajos Sándor Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Pályu Eszter (1983-) Udvardy Miklós (1947-) (belgyógyász, haematológus) Molnár Tamás (orvos Szeged) Farkas Klaudia Veres Gábor (1969-2020) (csecsemő- és gyermekgyógyász, gasztroenterológus) Hársfalvi Jolán (1949-) (klinikai biokémikus) Papp János (Budapest) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM002139
Első szerző:	Papp Mária (belgyógyász, gasztroenterológus)
Cím:	Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients / Papp M., Altorjay I., Norman G. L., Shums Z., Palatka K., Vitalis Z., Foldi I., Lakos G., Tumpek J., Udvardy M. L., Harsfalvi J., Fischer S., Lakatos L., Kovacs A., Bene L., Molnar T., Tulassay Z., Miheller P., Veres G., Papp J., Lakatos P. L.
Dátum:	2007
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Inflammatory Bowel Disease 13 : 8 (2007), p. 984-992. -
További szerzők:	Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Norman, Gary L. Shums, Zakera Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Földi Ildikó (1981-) (orvos) Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Tumpek Judit (1944-) (orvosi laboratóriumi szakorvos) Udvardy Miklós László (1977-) (orvos, tudományos segédmunkatárs) Hársfalvi Jolán (1949-) (klinikai biokémikus) Fischer Simon Lakatos László (orvos Budapest) Kovács Ágota Bene László (Budapest) Molnár Tamás (orvos) Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Miheller Pál Veres Gábor (1969-2020) (csecsemő- és gyermekgyógyász, gasztroenterológus) Papp János (orvos Veszprém) Lakatos Péter (Semmelweis Egyetem)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM036076
035-os BibID:	PMID:19637334
Első szerző:	Reinisch, Walter
Cím:	Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study / Walter Reinisch, Williem de Villiers, László Bene, László Simon, István Rácz, Seymour Katz, István Altorjay, Brian Feagan, Dennis Riff, Charles N. Bernstein, Daniel Hommes, Paul Rutgeerts, Antoine Cortot, Michael Gaspari, May Cheng, Tillman Pearce, Bruce E. Sands
Dátum:	2010
ISSN:	1078-0998
Megjegyzések:	BACKGROUND: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms. METHODS: A total of 201 patients with Crohn's Disease Activity Index (CDAI) scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 1.0 mg/kg fontolizumab or placebo every 4 weeks. Clinical response at day 29, the primary efficacy endpoint, was defined as a decrease in the CDAI of at least 100 points from baseline levels. RESULTS: Of 201 patients, 135 (67%) completed the study. Day 29 response rates were similar in all treatment groups (31%-38%). At subsequent timepoints a significantly greater proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab group had clinical response and significantly greater improvement in the CDAI score compared with patients who received placebo. All fontolizumab groups had significant improvement in C-reactive protein levels. The overall frequency of adverse events was similar in all groups (58%-75%); most events were related to exacerbation of CD. There was a low frequency (5.2%) of neutralizing antibodies to fontolizumab. CONCLUSIONS: Although a strong clinical response to fontolizumab was not observed, significant decreases in C-reactive protein levels suggest a biological effect. Fontolizumab was well tolerated, and further studies to assess its efficacy are warranted.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Inflammatory Bowel Diseases 16 : 2 (2010), p. 233-42. -
További szerzők:	Villiers, Williem de Bene László (Budapest) Simon László (orvos Szekszárd) Rácz István (orvos Győr) Katz, Seymour Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Feagan, Brian Riff, Dennis Bernstein, Charles N. Hommes, Daniel Rutgeerts, Paul Cortot, Antoine Gaspari, Michael Cheng, May Pearce, Tillman Sands, Bruce E.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: